Please note that since the NERCE program will end in February 2014, our ability to support new requests for services is limited.
Small Molecule Screening and Medicinal Chemistry Core
The screening core supports biodefense-related research directed towards the identification of small molecules that enhance our understanding of the basic biology of pathogens of biodefense or emerging infectious disease interest, and that may lead to the development of new therapeutic agents against these pathogens. The screening core:
Resources and Services available
Diverse screening platforms: the screening core supports any 96- or 384-well assay that can be read on a multimode plate reader (e.g., absorbance, fluorescence, luminescence) or by automated microscopy. Assays requiring special biocontainment are supported at lower throughput in conjunction with the NERCE Microbiology and Animal Resources Core.
Compound libraries: >500,000 small molecules are available for screening. The “known bioactives” libraries include ~ 50% of FDA-approved drugs. The screening core has also obtained a large number of partially purified natural product extracts (>65,000) via an ongoing collaboration with Dr. Jon Clardy (Harvard Medical School).
Full-time staff: the screening core collaborates with the ICCB-Longwood to provide a full-time staff with expertise in high-throughput screening, assay development, informatics, and medicinal chemistry. Staff will advise screeners at all stages of a screening project.
Medicinal chemistry: The screening core provides investigators with advice on hit triage, selection of positives for further study, preliminary structure-activity relationship (SAR) studies, and lead optimization plans. Synthesis of material for lead optimization studies and scale-up synthesis are available based on capacity and scientific merit. Medicinal chemistry support is also available for RCE-relevant projects that do not originate from HTS.
Application: Requests for support should be submitted to Gerald Beltz using a Core C request form:
Core C Request Form
Fees: There are no charges for projects focused on NIAID priority pathogens and agents of emerging infectious disease. NERCE also provides some supplies for approved HTS projects.
||Stephen Lory, Ph.D.
||Gerald A. Beltz, Ph.D.
Associate Director of Research